Enlivex Ltd. reported net income of $1.23 billion and diluted earnings per share of $25.48 for fiscal year 2025, with total treasury and treasury-related derivative assets reaching $2.31 billion. The company attributed much of its profitability to appreciation in these treasury assets, highlighting the effectiveness of its dual business model. Enlivex ended the fiscal year with total shareholders' equity of approximately $1.93 billion and maintained $30 million in cash, cash equivalents, and short-term investments in digital assets.
The company's financial performance stems from its distinctive dual-engine strategy, which combines a clinical-stage immunotherapy platform focused on quality longevity therapeutics with a treasury model anchored in the Rain decentralized prediction markets protocol. This structure provides public market investors with exposure to emerging prediction markets infrastructure while simultaneously advancing clinical development programs aimed at improving healthspan and quality of life. The company is progressing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with primary focus on age-related osteoarthritis.
Executive Chairman Shai Novik stated that the clinical engine continues to advance with Allocetra™ and its potential to restore mobility and independence in aging populations. In parallel, the treasury engine establishes exposure to prediction markets infrastructure through the Rain protocol, creating a capital strategy designed to align long-term shareholder value with the growth of decentralized forecasting markets. Together, these two engines position Enlivex to pursue innovation in quality longevity therapeutics while developing an innovative treasury model for a public company, which contributed to strong profitability based on unrealized appreciation in the company's treasury and treasury-related derivative assets.
The financial results underscore a significant development in corporate strategy, demonstrating how biotechnology companies can leverage emerging financial technologies to support research and development efforts. The integration of prediction markets through the Rain protocol represents a novel approach to treasury management that could influence how other companies in the longevity and biotechnology sectors structure their financial operations. For business and technology leaders, Enlivex's performance illustrates the potential financial benefits of combining traditional therapeutic development with exposure to decentralized financial infrastructure, creating a model that may be studied and potentially emulated across industries seeking innovative capital strategies.
To learn more about Enlivex's treasury strategy and read the full earnings report, visit https://www.benzinga.com. This content was originally published on Benzinga, where further disclosures are available at https://www.benzinga.com/disclosures.
